More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 120.6M
Share based compensation 15.3M
Gain on sale of non-current investments
Other
Movement in deferred taxes 16.6M
Equity in earnings of equity method investees 1M
Loss/(gain) on sale of product rights -5.2M
Changes in operating assets and liabilities:
Increase in accounts receivable -85.1M
Increase in sales deduction accrual -24.6M
Increase in inventory -22M
Increase in prepayments and other assets 42.4M
Decrease in accounts payable and other liabilities 77.5M
Net cash provided by operating activities 561.6M
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash -14.5M
Purchases of subsidiary undertakings, net of cash acquired -5.2B
Purchases of non-current investments -22.3M
Purchases of property, plant and equipment ("PP&E")
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 900K
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -5.18B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 2.23B
Repayment of debt acquired with ABH -535.2M
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 19.9M
Proceeds from exercise of options
Payment of dividend
Payments to acquire shares by ESOT
Net cash used in financing activities 1.71B
Net (decrease)/increase in cash and cash equivalents -2.91B
Effect of foreign exchange rate changes on cash and cash equivalents -1.6M
Cash and cash equivalents at beginning of period 2.98B
Cash and cash equivalents at end of period 74.3M
Supplemental information associated with continuing operations:
Interest paid -5M
Income taxes paid 48.8M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment